Analysis of the Related Factors in Hepatitis C Virus Infection Among Hemophilic Patients in Isfahan, Iran


Maziar Mojtabavi Naini 1 , * , Fatemeh Derakhshan 2 , Hamid Hourfar 2 , Roya Derakhshan 2 , Fariborz Makarian Rajab 3

1 Assistant Professor of Internal Medicine, Isfahan University of Medical Sciences, [email protected], IR.IRAN

2 Medical Student, Students Medical Research Committee, Isfahan University of Medical Sciences, IR.IRAN

3 Isfahan, IR.IRAN

How to Cite: Naini M, Derakhshan F, Hourfar H, Derakhshan R, Rajab F. Analysis of the Related Factors in Hepatitis C Virus Infection Among Hemophilic Patients in Isfahan, Iran, Hepat Mon. Online ahead of Print ; 7(2):59-62.


Hepatitis Monthly: 7 (2); 59-62
Article Type: Research Article
Received: September 17, 2006
Accepted: August 18, 2007


Background and Aims: Patients with hemophilia are at high risk of post-transfusion hepatitis because of widespread use of plasma-derived products. As a consequence, hepatitis C virus (HCV) is the most common cause of chronic liver disease among hemophilic patients. The objectives of this study are to determine HCV prevalence, and analyze the effective agents in HCV infection in hemophilic patients.
Methods: All patients with inherited coagulation disorders registered in hemophilia center of Isfahan (553 persons) were checked for HBsAg and anti-HCV, using enzyme-linked immunosorbent assay (ELISA) test. Positive tests for anti-HCV were confirmed by RT-PCR. Clinical history, laboratory and treatment data of all cases were studied in January 2006.
Results: From 465 men and 88 women with inherited coagulation disorders with the mean age of 23.4 ± 12.9 years, 125 patients (22.6%) were HCV positive, 2 (0.4%) were HBV positive and one (0.2%) was both HCV and HBV positive. Odds ratio between HCV infection and cryoprecipitate usage was 3 (CI 95%: 2-4.5) and between HCV and factor usage was 0.21 (CI 95%: 0.07-0.7).
Conclusions: Considering the high chance of HCV infection after transfusion of cryoprecipitate and, a more careful pre-transfusion screening of blood for anti-HCV must be introduced in all blood banks. The usage of FFP less chance of HCV infection, instead of cryoprecipitate in patients who do not have volume restrictions may be preferable.

© 0, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Full Text

Full text is available in PDF